TopFunds

Vertex Pharmaceuticals Incorporated

NASDAQ: VRTX

Stock price

499.74 USD

(+174.93%) 5 years

Biotechnology

Financial Performance

Share

5Y price score: 245

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 530.8%

DATE RANGE:

%

ㅤ

  • Earnings per share

  • Free cash flow per share

  • Stock price

Time scale:

By default your notes are visible only to you.

403.1

52-week range

560.2

499.74

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

3 %

Dividend Yield TTM

-

Market cap $

$ 126,665

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

29.1

Price / Book TTM

6.3

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

0

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

22.3 %

174.9 %

530.7 %

Free cash flow per share growth

10.6 %

8.9 %

827.3 %

Earnings per share growth

8 %

48.9 %

763.2 %

Founded: 1,989

Employees: 6,100

Business Summary:Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Q&A

SEARCH
Get answers on financials, industry, fundamentals or other questions.

Contribute

By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more

VIEW ALL Q&A

Contribute or ask questions about business following TopFunds community guidelines

Fair Value Reference Estimate

Latest Earnings Call Takeaways

2026 Q2 (Aug 3, 2026)

1) Strong Financial Performance and Growth Drivers
- Vertex reported Q2 2026 total revenue of $3.3 billion, a 12% YoY increase.
- Global CF revenue grew 11% YoY, with significant contributions from ALYFTREK and newer products CASGEVY ($76 million) and JOURNAVX ($50 million).
- The company raised its full-year revenue guidance to $13.1 billion to $13.2 billion, reflecting strong performance across its CF franchise and non-CF products.

2) Pipeline Advancements and Regulatory Progress
- Vertex is advancing its R&D pipeline, with key milestones including the acceptance of the BLA for Pove in IgAN, set for a November 30 PDUFA date.
- Enrollment in pivotal studies is progressing, with VX-407 in ADPKD and AMPLITUDE in AMKD on track for completion by year-end.
- The company is also preparing for the initiation of VX-017 Phase I/II study in type 1 diabetes, targeting a broader patient population.

3) Strategic Acquisition of Crinetics Pharmaceuticals
- Vertex announced a definitive agreement to acquire Crinetics Pharmaceuticals, adding a fifth pillar in rare endocrine diseases to its portfolio.
- The acquisition is expected to enhance Vertex's R&D pipeline and accelerate revenue growth, with peak sales potential of $5 billion from Crinetics' lead assets.
- The transaction is anticipated to close in Q3 2026, positioning Vertex for sustained growth.

4) Commercial Momentum in CF and Pain Franchises
- ALYFTREK surpassed $1 billion in revenue in H1 2026, with strong uptake in both the U.S. and Europe.
- CASGEVY's revenue growth reflects its recent FDA approval for pediatric use, while JOURNAVX is gaining traction with 70% sequential growth in revenue.
- The company is focused on expanding access and prescription growth for JOURNAVX, with ongoing efforts to secure broader payer coverage.

5) Challenges and Competitive Landscape
- Vertex faces competition in the IgAN space, particularly regarding eGFR outcomes from competitors, which may impact Pove's market entry.
- The company is also navigating the complexities of formulary access and reimbursement dynamics for JOURNAVX, which may affect revenue growth.
- Further details on competitive positioning and clinical data from ongoing trials are expected in upcoming months, particularly for AMPLITUDE and DM1 programs.

Bottom line: Vertex Pharmaceuticals is well-positioned for continued growth, driven by strong financial performance, a robust pipeline, and strategic acquisitions, despite facing competitive pressures and operational challenges in certain therapeutic areas.

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Vertex Pharmaceuticals Incorporated — Financial Overview, Stock Price, Market Cap

Vertex Pharmaceuticals Incorporated is a company. Founded in 1989. As of October 19, 2026, the company's market capitalization is $126664600140 with a current stock price of $499.74.